Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Immunol ; 208(9): 2227-2238, 2022 05 01.
Artigo em Inglês | MEDLINE | ID: mdl-35396222

RESUMO

Malignant ascites is a common clinical problem in ovarian cancer. NK cells are present in the ascites, but their antitumor activity is inhibited. The underlying mechanisms of the inhibition have yet to be fully elucidated. Using an Fcγ receptor-mediated NK cell activation assay, we show that ascites from ovarian cancer patients potently inhibits NK cell activation. Part of the inhibitory activity is mediated by CA125, a mucin 16 fragment shed from ovarian cancer tumors. Moreover, transcriptional analyses by RNA sequencing reveal upregulation of genes involved in multiple metabolic pathways but downregulation of genes involved in cytotoxicity and signaling pathways in NK cells purified from ovarian cancer patient ascites. Transcription of genes involved in cytotoxicity pathways are also downregulated in NK cells from healthy donors after in vitro treatment with ascites or with a CA125-enriched protein fraction. These results show that ascites and CA125 inhibit antitumor activity of NK cells at transcriptional levels by suppressing expression of genes involved in NK cell activation and cytotoxicity. Our findings shed light on the molecular mechanisms by which ascites inhibits the activity of NK cells and suggest possible approaches to reactivate NK cells for ovarian cancer immunotherapy.


Assuntos
Ascite , Antígeno Ca-125 , Células Matadoras Naturais , Neoplasias Ovarianas , Ascite/metabolismo , Antígeno Ca-125/genética , Antígeno Ca-125/metabolismo , Feminino , Humanos , Células Matadoras Naturais/metabolismo , Neoplasias Ovarianas/genética , Neoplasias Ovarianas/metabolismo , Ativação Transcricional
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa